A Novel Chemical Entity, Mary1, for the Treatment Mitochondrial Dysfunction, Vascular Injury, Kidney Diseases, and Organ Aging

This invention is a novel compound that can be used as a treatment for Acute Kidney Injury (AKI). This new method utilizes a small molecule agonist, capable of increasing mitochondrial biogenesis, which helps restore mitochondrial homeostasis and improves renal function and recovery. The compound showed beneficial effect in mouse model experiments.

Background: 
Acute kidney injury (AKI) is a decline in kidney function, typically following intensive operations, resulting in increased morbidity rates. In 2022, prognosis after hospitalization for AKI was poor, particularly for those who had undergone dialysis during their hospitalization. Currently, there is no FDA-approved drug for the treatment of AKI. The small molecule here has shown success in its ability to restore mitochondrial function via mitochondrial biogenesis. After selective receptor binding, renal function, mitochondrial, and cellular homeostasis are renewed.

Applications: 

• Novel compound therapeutics for treatment of:
  • Acute Kidney Injury (AKI) and other kidney diseases
  • Mitochondrial dysfunction
  • Vascular injury
  • Organ aging

Advantages: 

• Novel method of treatment 
• Agonist directly binds to receptor and induces great selectivity
• Restoration of renal function and recovery after AKI
• Reduction of renal fibrosis and vascular permeability
• Validated use in mouse model experiments